Advicenne Wins Prestigious Prix Galien – Medstartup Award for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcomes
October 26th, 2018
Award recognizes ADV7103 in development for the treatment of distal Renal Tubular Acidosis (dRTA).
Advicenne (Euronext: ADVIC), a specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today that it has been awarded the prestigious 2018 Prix Galien – Medstartup Award for Best Innovative Trial Design for ADV7103. The award was presented at a ceremony in New York City on October 25, 2018…